Friday, 10 Apr 2020

You are here

Adverse Effects of Low-Dose Methotrexate from the CIRT Trial

Low-dose methotrexate (LD-MTX) was studied in high risk cardiac patients in the cardiac intervention trial (CIRT), but was prematurely ended for not showing a change in cardiovascular event rates. Nonetheless this trial studied the safety and adverse event rates of LD-MTX and those results are reported in the current issue of Annals of Internal Medicine. 

This prospective randomized controll trial enrolled adults with known cardiovascular disease and diabetes or metabolic syndrome to receive either placebo or LD-MTX (≤20 mg/wk) or placebo and all received folic acid, 1 mg/d, 6 days per week.

Overall, 6158 patients were enrolled and 4786 randomly assigned to a treatment group with a median follow-up of 23 months and a median dosage 15 mg/wk.  There were more males (81%) and the patients were older (65.7 years) than those who usually receive MTX therapy (e.g., rheumatoid arthritis patients). 
The following adverse events were increased in the LD-MTX patients (compared to placebo)
  • Overall adverse events - hazard ratio [HR], 1.17 [95% CI, 1.10 to 1.25])
  • Gastrointestinal - HR 1.91 [CI, 1.75 to 2.10]
  • Pulmonary - HR 1.52 [CI, 1.16 to 1.98]
  • Infectious -  HR 1.15 [CI, 1.01 to 1.30]
  • Hematologic - HR 1.15 [CI, 1.07 to 1.23]
  • Skin cancer - HR 2.05 [CI, 1.28 to 3.28]   (Other cancers were not increased)
  • Renal AEs were reduced in the LD-MTX group - HR, 0.85 [CI, 0.78 to 0.93].
Specific AEs
  • MTX pneumonitis: thought to be a rare event, was seen in 6 patients on MTX vs. 1 on PBO  (HR, 6.94 [CI, 0.85 to 56.0], exact test P = 0.044); These cases in the LD-MTX group occurred between 2 and 27 months after randomization.
  • Pneumonia: was not increased with MTX therapy (HR 1.28; 0.89-1.83)
  • Risk of leukopenia (HR, 1.46 [CI, 1.19 to 1.80]) and anemia (HR, 1.36 [CI, 1.22 to 1.52]) were increased; not thrombocytopenia. Pancytopenia was rare.
  • Skin cancers (HR 2.0) - including basal-cell,  squamous cell and melanoma
  • Cirrhosis: there were 5 cases on MTX but none on PBO; none of the cirrhosis patients used alcohol but all were diabetic, and 3 of the 5 had repeated LFT abnormal labs (in >5/9 tests) 

Use of LD-MTX was associated with small to moderate elevations in risks for skin cancer and gastrointestinal, infectious, pulmonary, and hematologic AEs, whereas renal AEs were decreased.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The Immunologic Basis of Wellness in the COVID-19 Era

We indeed are living in interesting times and we all are seeking not to contract COVID-19 - this is logical. While our goal is to avoid infection, I think we all must agree that our aspirations must encompass more than disease avoidance. What we should be seeking now, as well, is more than absence of disease but rather a state of optimal wellness.

COVID Town Hall Meeting for Rheumatology

On Thursday, April 2nd, RheumNow hosted its' first Town Hall Meeting for Rheumatologist, with this 90 minute discussion devoted to the COVID-19 crisis as it affects Rheumatologists. 

The panel of six reknowned experts in rheumatology, practice, science, trials, telemedicine and infectious diseases included:

Universal Masking for COVID?

In early March 2020, there were widespread recommendations that wearing routine "surgical masks" by the public sector was not likely to be helpful or advisable. Now we are hearing of a 180 degree shift in thinking with the CDC, leading health officials and the current NEJM Perspective pointing to more widespread use of masks by healthcare workers and even by individuals in the public sector.

COVID Infection Run Down with Dr. Kevin Winthrop

Dr Kevin Winthrop answers COVID questions and advocates for "hit the pause button, lay low and exercise". We discuss the utility of baricitinib, losartan, COVID testing, Next Success and who to listen to.

Dr. Artie Kavanaugh - Don't Stop!

Drs. Cush and Kavanaugh discuss the downside of stopping hydroxychloroquine, DMARDs and biologics in lupus, RA and pregnancy.